
Rasarfin is a novel dual Ras and ARF6 ингибитор. Rasarfin blocks агонист-mediated internalization of AT1R and other GPCRs. Rasarfin also potently inhibits агонист-induced ERK1/2 signaling by GPCRs, and MAPK and Akt signaling by EGFR, as well as prevents cancer клетка proliferation. In silico modeling and in vitro studies reveal a unique связывание modality of Rasarfin within the SOS-связывание domain of Ras. Rasarfin is a novel dual Ras and ARF6 ингибитор. Rasarfin blocks агонист-mediated internalization of AT1R and other GPCRs. Rasarfin also potently inhibits агонист-induced ERK1/2 signaling by GPCRs, and MAPK and Akt signaling by EGFR, as well as prevents cancer клетка proliferation. In silico modeling and in vitro studies reveal a unique связывание modality of Rasarfin within the SOS-связывание domain of Ras.
Rasarfin is a novel dual Ras and ARF6 inhibitor. Rasarfin blocks agonist-mediated internalization of AT1R and other GPCRs. Rasarfin also potently inhibits agonist-induced ERK1/2 signaling by GPCRs, and MAPK and Akt signaling by EGFR, as well as prevents cancer cell proliferation. In silico modeling and in vitro studies reveal a unique binding modality of Rasarfin within the SOS-binding domain of Ras. Rasarfin is a novel dual Ras and ARF6 inhibitor. Rasarfin blocks agonist-mediated internalization of AT1R and other GPCRs. Rasarfin also potently inhibits agonist-induced ERK1/2 signaling by GPCRs, and MAPK and Akt signaling by EGFR, as well as prevents cancer cell proliferation. In silico modeling and in vitro studies reveal a unique binding modality of Rasarfin within the SOS-binding domain of Ras.
Вращайте мышью · Колесо — масштаб
Только для научно-исследовательского применения. Не предназначено для использования у пациентов или в качестве лекарственного средства.